ClinicalTrials.gg
RecruitingNCT07331363Updated Oct 29, 2026

Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening

An interventional study of Screening of the subjects was conducted using an ultrasonic robot. in Breast Cancer and Ultrasound, sponsored by Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to female participants aged 35 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 29, 2026Interventions changedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70,000
Allocation
Randomized
Ages
35 Years to 64 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
3rd of 1,525
70,000 · median 120
Started
2025
with 237 others
No phase
328 of 1,936
171 open now
Primary completion
2026-12
later than 514 of 1,067 live
Registered
1,714th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 3rd largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 238 that started in 2025, is one of 328 with no phase, reaches primary completion later than 514 of the 1,067 other live ones, and was the 1,714th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 35 Years to 64 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if robotic ultrasound screening works as well as or better than traditional sonographer-led screening for detecting breast cancer. It will also explore how well participants follow recommended post-screening care. The main questions it aims to answer are:

Does robotic ultrasound screening detect more cases of breast cancer compared to traditional sonographer-led screening? How well do participants follow up on recommended care after robotic ultrasound screening? Researchers will compare robotic ultrasound screening to traditional sonographer-led screening to see if robotic ultrasound works effectively for breast cancer screening.

Participants will:

Receive a breast ultrasound performed either by a robotic system or a human sonographer.

Undergo follow-up management based on their BI-RADS classification.

03

Conditions studied

  • Breast Cancer
  • Ultrasound

Browse trials for

04

Who can participate

Ages eligible
35 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women aged 35-64 years
  2. no history of breast cancer
  3. ownership and ability to use a smartphone
  4. willingness to participate in the screening program.

Exclusion criteria

Exclusion Criteria:

  1. Women who have undergone breast removal surgery;
  2. Pregnant and lactating women;
  3. Women who have undergone breast cancer screening within the past year;
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70,000 participants (estimated)

Study arms

  • Experimental
    ultrasound robot

    Device: Screening of the subjects was conducted using an ultrasonic robot.

  • No intervention
    traditional hand-held ultrasound

    The subjects are scanned with traditional hand-held ultrasound.The images are diagnosed by radiologists.

Interventions

  • DeviceScreening of the subjects was conducted using an ultrasonic robot.

    The ultrasound robot automatically scans the breasts of subjects via its mechanical arm and generates images.The diagnosis is made based on the radiologist's interpretation of the images.

06

What researchers measure

Primary outcomes

  1. The detection rate of breast cancer

    Number of detected ductal carcinoma in situ (DCIS) and invasive breast cancers divided by the total number of screened participants.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

Secondary outcomes

  1. Cancer type

    Non-invasive cancer (DCIS), early invasive cancer, and invasive cancer.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  2. The early diagnosis rate

    The early diagnosis rate is defined as the number of breast cancer cases with TNM stage 0, I, or IIa divided by the number of women diagnosed with breast cancer or other malignant breast tumors during screening\*100.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  3. Lymph node status

    Presence of lymph node metastasis; size, morphology, internal structure, margin characteristics, and vascularity of metastatic lymph nodes.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  4. Breast cancer clinical stage

    TNM staging, representing tumor size (T), lymph node involvement (N), and distant metastasis (M).

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  5. Histological Grading of Breast Cancer

    The internationally accepted Nottingham Histological Grading System is used. This system provides a semi-quantitative and objective assessment of invasive breast cancer. It evaluates three parameters: the proportion of tubule formation, nuclear pleomorphism, and mitotic count. The scores of the three parameters are added together. A total score of 3-5 indicates Grade 1 (G1, well-differentiated/low grade). A total score of 6-7 indicates Grade 2 (G2, moderately differentiated/intermediate grade). A total score of 8-9 indicates Grade 3 (G3, poorly differentiated/high grade).

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  6. Breast cancer screen recall rate

    Breast cancer screen recall is defined as further assessment triggered by abnormal ultrasound findings (BI-RADS 0 or 3 and above). The recall rate is the number of women actually recalled divided by the number of women screened.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  7. The positive predictive value

    The positive predictive value of recall is the percentage of recalled women who are diagnosed with breast cancer.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  8. The breast cancer biopsy rate

    The breast cancer biopsy rate is defined as the number of women who actually underwent biopsy divided by the number of women screened. The positive predictive value of biopsy is defined as the percentage of women diagnosed with breast cancer among those who received a biopsy.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  9. Referral adherence rate

    Defined as the average adherence to recommended referral for confirmed diagnosis (biopsy and histopathology). It is calculated as the number of women actually referred divided by the number of women recommended for referral.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  10. Interval cancer incidence

    Defined as the proportion of women who had a negative or false-positive screening (i.e., no ductal carcinoma in situ or invasive breast cancer) and were subsequently diagnosed with invasive breast cancer within a certain period after screening. Following the national breast cancer screening guideline recommending screening every 2-3 years, this study will evaluate the interval cancer incidence at 24 months, i.e., the proportion of women diagnosed with breast cancer 24 months after a negative screen or 6-24 months after a false-positive screen.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  11. Breast cancer mortality

    Defined as the number of deaths due to breast cancer within 24 months after screening divided by the total number of women screened.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  12. All-cause mortality

    Defined as the total number of deaths from any cause within 24 months after screening divided by the total number of women screened.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

  13. Post-screening management adherence

    Defined as the proportion of women who completed the recommended follow-up medical actions after screening (referral, re-examination, additional tests, etc.). The adherence rate is calculated as the number of participants who completed the recommended management within the specified time / the number of participants requiring further management \* 100%.

    Time frame: After participating in the screening, the subjects will be followed up for 24 months.

07

Study locations

1 of 1 sites recruiting
  • Rural health centers and community health centers
    Xiantao, Hubei 433000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Jan 9, 2026
StartActual
Dec 10, 2025
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Arm changed The subjects are scanned with traditional hand-held ultrasound.→traditional hand-held ultrasound; Intervention group: Using an ultrasound robot to screen the subjects→ultrasound robot
Oct 29, 2026
Title
Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening: A Multicenter, Parallel-group, Cluster Randomized Controlled Trial
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Interventions Arm changed The subjects are scanned with traditional hand-held ultrasound.→traditional hand-held ultrasound; Intervention group: Using an ultrasound robot to screen the subjects→ultrasound robot
    Title Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening: A Multicenter, Parallel-group, Cluster Randomized Controlled Trial
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07331363
Responsible party
Xiaoxv Yin, PhD (Professor, Huazhong University of Science and Technology) — Principal investigator
First posted
Jan 9, 2026
Start date
Dec 10, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Xiaoxv Yin, Doctor
Contact
yxx@hust.edu.cn
86+13871187781

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion